Tretinoin 0.1% and Benzoyl Peroxide 3% Cream for the Treatment of Facial Acne Vulgaris
Annals of Pharmacotherapy · 2023
DOI: 10.1177/10600280221147338 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Annals of Pharmacotherapy, 2023. Verfasst von Christina Kontzias und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA. Hauptthemen laut MEDLINE: Acne Vulgaris, Dermatologic Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Objective
To assess the efficacy, safety, and clinical application of tretinoin 0.1%-benzoyl peroxide 3% cream for the topical treatment of acne vulgaris. Data Sources: A systematic review of the literature was performed using the terms Twyneo OR tretinoin and benzoyl peroxide OR S6G5T-3 in MEDLINE (PubMed) and EMBASE. ClinicalTrials.gov was searched to obtain completed clinical trial results not published elsewhere. Study Selection and Data Extraction: All human studies published in English prior to November 2022 related to pharmacology, clinical trials, safety, and efficacy were evaluated for inclusion. Data Synthesis: In two 12-week, phase 3, randomized, vehicle-controlled clinical trials, tretinoin 0.1%-benzoyl peroxide 3% cream significantly reduced inflammatory and noninflammatory facial acne lesions and significantly improved Investigator Global Assessment (IGA) rating to clear or almost clear. The cream has a suitable safety profile, with application site pain and dryness as the most common adverse events. Relevance to Patient Care and Clinical Practice in Comparison to Existing Agents: Tretinoin-BPO had similar IGA success compared to other topical retinoid and retinoid-BPO treatments for acne vulgaris. Compared to individual tretinoin and benzoyl peroxide therapy, the combination product streamlines application, which will improve medication adherence; however, the cost of tretinoin-BPO cream may be prohibitive.
Conclusions
Tretinoin 0.1%-benzoyl peroxide 3% cream is safe and effective for the treatment of moderate-to-severe acne. Long-term trial data on efficacy and tolerability are not yet available.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
- Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
- Department of Social Sciences and Health Policy, Wake Forest School of Medicine, Winston-Salem, NC, USA.
ORCID-Profile: Christina Kontzias
Zitieren
APA
Kontzias, C., Zaino, M., & Feldman, S. R. (2023). Tretinoin 0.1% and Benzoyl Peroxide 3% Cream for the Treatment of Facial Acne Vulgaris. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280221147338
Vancouver
Kontzias C, Zaino M, Feldman SR. Tretinoin 0.1% and Benzoyl Peroxide 3% Cream for the Treatment of Facial Acne Vulgaris. Annals of Pharmacotherapy. 2023. doi:10.1177/10600280221147338
BibTeX
@article{Kontzias2023,
author = {Kontzias, Christina and Zaino, Mallory and Feldman, Steven R},
title = {Tretinoin 0.1% and Benzoyl Peroxide 3% Cream for the Treatment of Facial Acne Vulgaris},
journal = {Annals of Pharmacotherapy},
year = {2023},
doi = {10.1177/10600280221147338}
}
EUVIMED